|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1766 - 0.1900|
|52 Week Range||0.1380 - 0.8200|
|Beta (5Y Monthly)||4.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hand-crafted, small-batch, East Coast cannabis launches with four distinctive strains for discerning connoisseurs Survey finds that Atlantic Canadians believe the best-quality cannabis is cultivated on the East Coast, with British Columbia coming out on top nationallyTORONTO, July 27, 2020 (GLOBE NEWSWIRE) -- Cannabis connoisseurs, the wait is over. Today, Robinsons hand-crafted, small-batch cannabis is available in Ontario and Nova Scotia. Robinsons is launching with four distinctive strains, all grown with care at the 27,700 sq. ft. Robinsons facility in Kentville, Nova Scotia, with an uncompromising commitment to quality and craftsmanship. Robinsons, the latest brand to be launched by Auxly Cannabis Group (TSX.V - XLY) (“Auxly”), is focused on exceptional cannabis and cannabis products for discerning consumers.“I’m so excited to share the result of my life’s passion for cannabis,” said Robinsons Founder and Master Grower, Andrew Robinson. “Cannabis is a beautiful, diverse, and complex plant. Our team hand-tends each plant every step of the way to ensure optimal taste, aroma and appearance. I hope Canadian cannabis lovers enjoy it as much as I do.”“I believe that Robinsons is growing some of the best cannabis in Canada and I am very excited and proud that we are bringing it to the market,” said Hugo Alves, CEO, Auxly. “Ontario and Nova Scotia are just the beginning, and we look forward to sharing Robinsons with discerning consumers in other provinces in the coming months.”A Media Snippet accompanying this announcement is available by clicking on the image or link below: Robinsons’ focus on quality and flavour results in a uniquely premium product for the cannabis connoisseur. Robinsons’ plants are grown in a 100% peat-based soilless mix created to optimize every element of growth. Proprietary methods ensure ideal water drainage, retention and airspace for each individual plant, which are rigorously monitored and tended so the flowers achieve optimal nutrient availability for growth and development.At each stage, from potting, to trimming, to packaging, Robinsons cultivators carefully oversee and hand-tend to each plant, leaf and bud. Robinsons’ commitment to delivering only the highest-quality product possible culminates in the harvest. When ready, each bud goes through two rounds of hand-manicuring before entering a climate-controlled drying room. The result is premium cannabis with a taste, aroma, and appearance that is uniquely Robinsons. To preserve the integrity and freshness of the product, Robinsons cannabis is packaged by hand in light-proof glass jars.Robinsons is launching with four distinct strains: * Lemon Garlic OG. A potent Indica-dominant Hybrid with densely stacked, frosty lime-green buds, Lemon Garlic OG was developed through intensive plant selection and breeding over generations. With spicy notes of pine, citrus and garlic, this distinctive strain contains high THC levels with virtually no CBD present. * Fire OG. Fire OG derives its name from the frosty, trichome-rich buds it produces. Neon green with thin red hairs, Fire OG’s strong lemon scent transforms into a pungent earthy aroma with undertones of sweet pine when burned. An Indica-dominant Hybrid, this robust strain contains high THC levels. * GG4. Sweet notes of chocolate and coffee offset the pungent, diesel aroma of Gorilla Glue. Densely stacked, its chunky, resin-covered buds are bright green with orange hairs, showcasing an abundance of trichomes. This potent Balanced Hybrid strain contains high THC levels and produces a strong, skunky perfume when burned. * Purple Kush. A heavy-hitting cross between Hindu Kush and Purple Afghani, Purple Kush is easily identified by its unique purple and orange buds. With a subtle, earthy aroma, this Indica-dominant Hybrid contains sweet, hallmark notes of berry and grape, and high THC levels.Robinsons is launching with 3.5 gram units and is available in Ontario at retail outlets across the Province as well as the OCS and in Nova Scotia at the NSLC.Robinsons aims to challenge the public’s perception about which region in the country produces the highest-quality cannabis. According to a recent survey commissioned by Robinsonsi, 44% of Canadians nationally said that they expect the best quality cannabis is cultivated on the West Coast in British Columbia – the top-ranked region in Canada. However, among respondents from Atlantic Canada, the East Coast takes top honours, with 48% saying that Atlantic Canadian cannabis is the best. These results indicate regional pride in cannabis cultivation, which is echoed in regional responses across the country.About Robinsons Robinsons is a premium cannabis brand, wholly owned by Auxly Cannabis Group Inc. Proudly grown in a 27,700 sq. ft., purpose-built, state-of-the-art indoor cultivation facility in Nova Scotia’s famed Annapolis Valley, Robinsons’ small-batch, hand-tended cannabis is the result of proprietary cultivation techniques honed from a lifelong pursuit of excellence. Robinsons is available at licensed cannabis retail outlets in Ontario and Nova Scotia.Learn more at robinsonscannabis.com and stay up-to-date at Twitter: @robinsonscanna; Instagram: @robinsonscannabis; Facebook: @robinsonscannabis.About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly's experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.For more information please contact: Scott Campbell, 647-402-4957, email@example.com Notice Regarding Forward Looking Information:This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the proposed operation of the RCI facility; consumer preferences, political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to whether: there is acceptance and demand for Robinsons products by consumers and provincial purchasers; and general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. Readers should not place undue reliance on forward-looking information contained in this release. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.____________________________ i Maru/Blue survey of 1,5108 randomly selected Canadian adults, conducted on June 16th, 2020.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, Dosecann LD Inc. (“Dosecann”) has received its Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. This licence permits Dosecann to administer cannabis extracts, edible cannabis and cannabis topicals to human subjects for purposes of palatability and sensory testing at its state-of-the-art facility located in Charlottetown, Prince Edward Island. Dosecann has spent the last few years developing highly accurate, proprietary processes in order to create the Company’s first-class suite of cannabis products, however, due to regulatory restrictions, the product development team was unable to fully evaluate the impact of cannabis infusion on the taste of its edible products.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a consumer packaged goods company in the cannabis products market, today provided an update on the Company’s national and international cultivation strategy. The Company is pleased by the progress of its cultivation portfolio, which is instrumental in supplying a secure, cost-efficient and consistent source of input material for the Company’s growing portfolio of cannabis products. In order to sharpen the Company’s near-term focus on Cannabis 2.0 dominance in Canada, the Company has decided to rationalize its cultivation portfolio by focusing on its domestic cultivation, while maintaining optionality in Uruguay.
TORONTO, June 26, 2020 -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”) has issued an additional $3 million worth of unsecured convertible.
The Company is strongly discouraging physical attendance at the meeting to proactively deal with potential issues arising from the unprecedented public health impact of COVID-19 and to limit and mitigate risks to the health and safety of its communities, shareholders, employees, directors and other stakeholders. The Meeting will not be open to the general public and will be restricted to registered shareholders (who are also strongly discouraged from attending) and duly appointed proxyholders only. To ensure compliance with public health guidance on public gatherings, registered shareholders who wish to attend the Meeting are required to provide the Company with at least 48 hours advance notice, and any shareholder who does not provide such notice and receive approval from the Company to attend will not be admitted to the Meeting.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a leading consumer packaged goods company in the derivative cannabis products market, is pleased to announce that its wholly-owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with GSW Creative Corporation Canada Inc., doing business as dosist™ (“dosist”), to manufacture their proprietary wellness vape devices at Dosecann’s facility in Prince Edward Island. “We are thrilled to expand the Dosecann business to include the manufacture and distribution of dosist’s proprietary wellness devices,” said Hugo Alves, CEO of Auxly. Also, as a premium wellness-focused brand with an international track record of success in California and here in Canada, dosist is a perfect fit within Auxly’s existing portfolio of branded cannabis products.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a consumer packaged goods company in the cannabis products market, is pleased to announce that its joint venture partner, Sunens Farms Inc. (“Sunens”), has secured a standard cultivation licence from Health Canada for the first phase of its fully automated, purpose-built, 1.1 million sq. ft. greenhouse facility in Leamington, Ontario. The Sunens facility is operational and the team will immediately begin cultivating high-quality organic cannabis within the licensed area. This standard cultivation licence allows Sunens to commence bulk sales of cannabis following harvest without additional regulatory approvals.
Under the Third Tranche, the convertible debentures issued to the Investor have a conversion price of $0.38 per common share of the Company (each a “Common Share”), and the Investor received warrants to purchase 4,342,105 Common Shares until June 8, 2022 at an exercise price of $0.46 per Common Share. Each convertible debenture will mature on June 8, 2022 and will bear guaranteed interest from the date of issue at 7.5% per annum, payable semi-annually on June 30 and December 31 of each year and has the same terms and conditions as described in the Original Offering and the transaction documents filed on the Company’s SEDAR profile.
One thing we could say about the analysts on Auxly Cannabis Group Inc. (CVE:XLY) - they aren't optimistic, having just...
It's been a good week for Auxly Cannabis Group Inc. (CVE:XLY) shareholders, because the company has just released its...
Sales were strong in British Columbia, Alberta and Ontario comprising more than 80% of the Company’s revenues, with vapes accounting for more than 65% of its cannabis revenues. Auxly realized a gross profit of $2.8 million following fair value adjustments during the first quarter of 2020, as compared to a gross loss of $0.2 million during the first quarter of 2019.
Under the Second Tranche, the convertible debentures issued to the Investor have a conversion price of $0.425 per common share of the Company (each a “Common Share”), and the Investor received warrants to purchase 2,588,235 Common Shares until May 21, 2022 at an exercise price of $0.51 per Common Share. Each convertible debenture will mature on May 21, 2022 and will bear guaranteed interest from the date of issue at 7.5% per annum, payable semi-annually on June 30 and December 31 of each year and has the same terms and conditions as described in the Original Offering and the transaction documents filed on the Company’s SEDAR profile.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a consumer packaged goods company in the cannabis products market, is pleased to announce that its wholly owned subsidiary Robinsons Cannabis Inc. (“Robinsons”) has been authorized by Health Canada to sell dried cannabis to provinces and territories under the Cannabis Regulations. This sales licence expands Auxly’s product portfolio to include artisan hand-crafted cannabis flower for the premium craft market, which the Company expects to be available in select Canadian provinces this summer. “We couldn’t be more excited to obtain this sales licence for Robinsons – a key milestone for Auxly as we continue to execute against our vision of being a leader in branded cannabis products,” said Hugo Alves, CEO of Auxly.
TORONTO, April 29, 2020 -- Auxly Cannabis Group Inc. (TSX.V - XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"), a consumer packaged goods company in the cannabis products market,.
This provides the Company with the opportunity to sell, on a private placement basis, unsecured convertible debentures of the Company (collectively, the “Convertible Debentures”) in the principal amount of up to $25,000,000 (the "Offering"). The Convertible Debentures will be issuable in tranches at the request of the Company, as described in greater detail below.
Auxly Cannabis Group Inc. (TSX.V - XLY) (“Auxly” or the “Company”), a leading consumer packaged goods company in the derivative cannabis market, today announced that Kolab Project, the Company’s platform dedicated to art, design and culture, has partnered with OCAD University (“OCAD U”), the oldest, largest and most comprehensive art, design and media university in Canada. Among other initiatives developed to enhance the community experience, foster faculty innovation and enrich academic programming at OCAD U, Kolab Project will collaborate with OCAD U’s Centre for Emerging Artists & Designers (CEAD) through the development of design-focused working placements and create and support art exhibit opportunities for OCAD U.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a leading consumer packaged goods company in the derivative cannabis market, is pleased to announce that its wholly-owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with Medical Cannabis by Shoppers Drug Mart Inc. (“Shoppers”), a subsidiary of Shoppers Drug Mart Inc., to become a supplier of cannabis products through its online platform. Dosecann has completed its initial shipment of cannabis products to Shoppers.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a leading consumer packaged goods company in the derivative cannabis market, is pleased to announce that its wholly owned subsidiary Dosecann LD Inc. (“Dosecann”) has entered into an agreement with Natures Crops International (“Natures Crops”), a vertically integrated grower and manufacturer of plant-based specialty oils, pursuant to which the Company will purchase the exclusive global rights to Ahiflower® oil for use in Auxly’s diverse portfolio of cannabis products. This multi-year deal will provide Auxly with a proprietary ingredient for use in its current portfolio of cannabis products and the development of next generation cannabis health products that Auxly will commercialize when legally permitted.
Alan Cooke has joined Auxly as Vice President, Domestic and International Supply Chain and Operations. “Auxly’s management team is committed to the long-term success of the Company and feel more confident than ever in executing on our growth strategy with Alan bringing his extensive experience to our operations team,” said Hugo Alves, CEO.
Auxly Cannabis Group Inc. (TSX.V - XLY) (“Auxly” or the “Company”) is pleased to announce that it has entered into a supply agreement with its strategic partner, Delta 9 Cannabis Inc. (“Delta 9”) in which the Company will supply cannabis products to Delta 9’s multiple retail locations, where permitted. Delta 9 is a vertically integrated cannabis company based in Winnipeg, Manitoba. Delta 9 currently operates four cannabis retail stores in Manitoba, with plans to build out a chain of retail stores under the Delta 9 Cannabis Store brand.
TORONTO, Jan. 22, 2020 -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”) is pleased to announce that it has been included in the newly created.
In addition, warrants issued on January 16, 2018 to purchase 32,200,000 shares of the Company’s common stock at a strike price of $1.80 expired as of January 16, 2020. The warrants, which traded under the TSX venture symbol XLY.WT.A, have been delisted. “The repayment of the remaining debentures, together with the expiration of the 2018 warrants, has simplified our capital structure,” said Hugo Alves, CEO of Auxly.
The Canadian cannabis sector just can’t get regulators out of its way. The Cannabis 2.0 products were finally made available on December 17, yet a large portion of the provinces won’t allow key vape sales.Last week, Alberta suspended the sales of cannabis vaping devices due to the concerns around their health effects despite signs that the vaping health issues are related to illegal vape products. While the regulatory agency has made it clear that this move is only a suspension, Canadian cannabis companies can’t afford more delays.The Cannabis 2.0 products like vapes, edibles and topicals were supposed to carry higher margins and Eight Capital has vapes accounting for 20% of the market. A big profit driver of the market is now removed as Alberta isn’t the only province pushing back on vapes.Quebec has banned vapes and most 2.0 products. In addition, Newfoundland and Labrador have suspended vapes and British Columbia slapped a 20% tax on vape product sales. Ontario also has major cannabis retail store issues.The new plan released by the Alcohol and Gaming Commission of Ontario (AGCO) has guidelines for companies submitting store applications on March 2, with a goal of ultimately approving up to 20 retail locations per month starting in April. In total, Ontario is set to add 180 new stores next year and reach 250 stores by the end of 2020.The Ontario market includes the key Toronto metro area and nearly 40% of the total Canadian population of 37 million. The Alberta and Quebec provinces add another 35% of the population blocked from the vape market. Only a fraction of the Canadian market has easy access to buy vape products and virtually no part of the population has cheap access to vapes.We’ve delved into three companies that were set to benefit from vapes, but are now positioned to struggle until Ontario adds more retail stores and Alberta and Quebec remove the suspension on selling vape products:Aphria (APHA)Back in July, Aphria signed a deal with PAX Labs for their premium cannabis vaporization devices. At the time, the company estimated vapes and concentrates will represent 30% of the entire Canadian adult-use market by 2021. In addition, the company plans to strategically market edibles, beverages and topicals, with the hope that these products will eventually make up 10% of total sales.Amongst the large Canadian LPs, Aphria is the least promotional on new product formats. The company forecasts strong sales from the category without really drumming up the actual products.Aphria has a stated goal of reaching a C$1 billion annual revenue run rate at the end of 2020 with higher margins. The question one has to ask is whether the company can reach those targets without a full 30% of revenues coming from vapes and concentrates along with the much higher margins.The FY20 forecast for revenues reaching nearly C$700 million would presumably require a substantial boost from vape sales. When the company reports FQ2 earnings in mid-January, the market will zero in on any update to financial targets after the initial weeks of Cannabis 2.0 sales and the general lack of availability of vape sales so crucial to hitting revenue targets.While there are concerns, Wall Street analysts generally remain optimistic. The Moderate Buy analyst consensus breaks down into 6 Buy ratings and 1 Sell received in the last three months. Not to mention the $8.51 average price target puts the upside potential at 74%. (See Aphria stock analysis on TipRanks) OrganiGram Holdings (OGI)OrganiGram just announced the release of their first Cannabis 2.0 products. Several versions of their 510-thread vape cartridges have been shipped to Manitoba, Saskatchewan, Ontario, New Brunswick and Nova Scotia from the company’s Moncton production campus.The only meaningful province on the list is Ontario where sales aren’t going to be significant with only 24 retail stores open in the province. OrganiGram is one of the first companies with vape products on the market, but the company doesn’t have a market to sell to.OrganiGram is offering cartridges with three distinct offerings, Spark (sativa-dominant), Flicker (hybrid) and Glow (indica-dominant), inspired by dried flower and pre-roll products under the company’s Trailblazer-branded product lineup.It plans to release other vaporized products over the next month including Edison + Feather ready-to-go distillate pens and Edison + PAX ERA distillate cartridges. Other products set for Q1 and Q2 release are infused chocolates and dissolvable powdered beverage products designed for faster onset of cannabinoids.However, analysts only expect sales for FQ2 to reach $18.8 million. This isn’t even close to the peak levels from last year. Investors have to expect actual numbers to miss sales estimates due to the lack of any meaningful sales outlet for vapes.Despite this, analysts aren’t giving up on OGI just yet. Looking at the consensus breakdown, 5 Buys and 2 Holds add up to a Moderate Buy. On top of this, the $6.14 average price target suggests shares could soar 161% in the twelve months ahead. (See OrganiGram price targets and analyst ratings on TipRanks) Auxly Cannabis (CBWTF) Auxly Cannabis Group is one of the smaller Canadian cannabis companies offering a full suite of Cannabis 2.0 products. The vapes are based on technology from major investor Imperial Brands (IMBBY). The company has two brands releasing different vape products with various levels of THC and CBD formulations.The Toronto based company has over 250 listings for Cannabis 2.0 products across nine provinces that cover vape, chocolate and chewable products. In total, Health Canada approved 83 derivative cannabis products for this rollout.The recent Q3 report showed revenues of only C$1.6 million, mostly for research contracts. Additionally, analysts project 2020 revenues will reach $65 million, with a lot of the forecast revenue being based on vape sales.The stock has a listed market valuation of $276 million so the biggest risk is the lack of access to vape customers, which hurts projected growth of a company still in startup mode. (See Auxly stock-price forecast and analyst ratings) Check out these 5 ‘Strong Buy’ stocks that top Wall Street analysts recommend.Disclosure: No position. Disclaimer: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities.
Imperial Brands has subscribed for the Purchased Shares to maintain its pro rata ownership in Auxly as follows: i) 914,960 common shares at a subscription price of $0.91 per share; and ii) 5,400,614 common shares at a subscription price of $0.81 per share, issuable to Imperial Brands; for the issuance of shares to non-executive employees and for the remaining 6% unsecured convertible debentures. “We are delighted that Imperial Brands continues to support our vision of being a global leader in branded cannabis products,” said Hugo Alves, CEO of Auxly.
Auxly Cannabis Group Inc. (TSX.V - XLY) (“Auxly” or the “Company”) today announced the unveiling of its “Cannabis 2.0” products in vape, chocolate and chewable formats which are legally available for sale beginning today under its signature brands, Kolab Project, Foray and Dosecann. “Having our initial suite of Cannabis 2.0 products ready to go on the first day sales are legal in Canada is a huge milestone for our company," said Hugo Alves, CEO, Auxly.